



Over £500M Investment made in life-science companies located at the Babraham Research Campus, Cambridge over last two years.

Babraham Cambridge – (30th November 2016).

The recent announcement from Kymab on the closing of \$100M investment series 'C' funding brings the total amount of investment raised by companies located on the Babraham Research Campus over the last two years, to be in excess of £0.5 Billion.

Since late 2014 over £500M of new investment into life science companies on the campus has been achieved and publicly announced. These investments come from a broad range of sophisticated investors from US, UK, EU, and Asia, demonstrating the international competitiveness and attraction of Cambridge based life science companies. Investors have included Chinese venture capital, The Wellcome Trust, Bill and Melinda Gates Foundation, Woodford Investment Management, and corporate and corporate venture capital investments from leading pharmaceutical and technology companies such as Johnson & Johnson, Pfizer, Google, Takeda and Biogen Idec.

The top deals include:

Company	Amount¹	Date
Convergence	\$200M	Jan 2015
Kymab	\$190M	May 2015, Nov 2016
Mission Therapeutics	£60M	Feb 2016
F-star	\$50M	Oct 2014
Crescendo Biologics	\$36M	Oct 2016
Artois	\$33M	Sep 2016
Abzena	£20M	Nov 2015
Bicycle	£20M	Oct 2014
CEGX	\$21M	Mar 2016
Storm Therapeutics	£12M	Jun 2016

In addition, in March 2015, X01 was sold for an undisclosed sum to Janssen Pharmaceuticals part of Johnson & Johnson. Others companies on the campus at an earlier stage of their development announcing additional funding include Phico Therapeutics who raised an additional £3.5M in November 2016.

Commenting on these numbers, Derek Jones, CEO of Babraham Biotechnologies Ltd - the organisation responsible for the development and management of the Babraham Research campus - said, "One key measure of the success of the Babraham Research Campus, is the value of, and the sums raised by companies on site. Many of these companies established themselves at Babraham as start-ups, and have grown with the campus. Scale-up companies - those companies growing rapidly beyond 'start-up' are of increasing importance to our economy. These deals demonstrate the number and ambition of scale-up companies on site. I hope that the facilities, capabilities, networks and

¹ Given in the currency provided in the announcements.

community on the campus which have created and continue to nurture provides a supportive and encouraging environment for companies to start-up and grow here. It is also encouraging to acknowledge the continued investment in Cambridge life sciences post the Brexit decision.”

About Babraham Research Campus

Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.

The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organisation which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organisations. The Campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute.

Derek Jones
Chief Executive, Babraham Bioscience Technologies
derek.jones@babraham.co.uk
www.babraham.com